Hyloris announces U.S. FDA Approval of Maxigesic IV (GlobeNewswire) - Oct 18, 2023 - "Hyloris Pharmaceuticals SA...announces Maxigesic® IV has been approved for the relief of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics in adults, where an intravenous route of administration is considered clinically necessary. The approval for the New Drug Application (NDA) is based on positive data from a Phase 3 program..."
sNDA • CNS Disorders • Pain
|